Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
doi: 10.3390/microorganisms10051065 545 ZhengPXFangHYYangHBTienNYWangMCWuJJ
A foundational element of GEMMABios early program portfolio came from an out-licensing and collaboration agreement with Passage Bio, under which the company acquired three pediatric lysosomal storage disease programs, targeting GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy, giving GEMMABio immediate, clinical-stage assets to advance
Sheerin et al., 2004)
Its unique ability to cross the blood-brain barrier further augments its potential benefits, especially concerning weight management
Although frequently used to examine MC4-mediated appetite signaling, experimental studies require subtype-specific controls to distinguish receptor-dependent effects accurately
The receptor activation profile across the experiment is non-uniform
